CDKN1A and glioblastoma: Through genotyping analysis of CDKN1A, we made a novel finding, establishing a significant association between GBM patient survival and the presence of either arginine homozygotes (Arg/Arg) or serine/arginine heterozygotes (Ser/Arg) at codon 31 of CDKN1A, particularly following bevacizumab therapy in a Chinese population.